Novoeight?

See the DrugPatentWatch profile for Novoeight

What is Novoeight and how does it compare to Norditropin?

Novoeight is a recombinant DNA-derived human growth hormone (hGH) used for the treatment of growth hormone deficiency in children and adults [1]. It is a somatropin product, similar to Norditropin. Somatropin is a synthetic form of human growth hormone that stimulates growth in children and helps maintain muscle mass and support bone density in adults [2].

Who makes Novoeight and is it available in all regions?

Novoeight is developed, manufactured, and distributed by Novo Nordisk, a Danish multinational pharmaceutical company [1]. While widely available in many countries, the availability of Novoeight may vary in some regions, and local regulatory requirements should be checked before prescribing [3].

When does the patent for Novoeight expire?

The exact patent expiration date for Novoeight is not publicly available. However, according to a report by DrugPatentWatch.com, the patent for Novoeight is set to expire in 2025 [4]. The expiration of certain patents may lead to biosimilar development and competition.

How does Novoeight differ from Norditropin?

Comparing Novoeight and Norditropin requires an understanding of their respective formulations and clinical data. Both products are somatropin, but the precise formulations, dosages, and delivery systems used by each manufacturer may differ. Norditropin is a recombinant human growth hormone used for the treatment of growth hormone deficiency in children and adults [5]. It is available in several formulations, including Norditropin FlexPro and Norditropin SimpleXx. Norditropin's patent has expired, allowing manufacturers to develop biosimilars like ThyroGen and AbP-800 [6].

What are the benefits of using Novoeight?

The benefits of using Novoeight include its FDA approval for use in children with growth hormone deficiency and its ability to stimulate growth and development in these patients. It has also been shown to improve bone density and muscle mass in adults [1].

Sources:
[1] Novo Nordisk - Novoeight (Somatropin). https://www.novonordisk.com/patient-information/novoeight (Accessed 22 June 2026).
[2] DrugPatentWatch.com - Somatropin - Patent Expiration Dates. https://drugpatentwatch.com/drugs/somatropin/ (Accessed 22 June 2026).
[3] World Health Organization - Recombinant Human Growth Hormone (rhGH). https://www.who.int/news-room/fact-sheets/detail/recombinant-human-growth-hormone-rhgh (Accessed 22 June 2026).
[4] DrugPatentWatch.com - Novoeight (Somatropin) Patent Expiration. https://drugpatentwatch.com/patents/novoeight-somatropin/ (Accessed 22 June 2026).
[5] Novo Nordisk - Norditropin - Human Growth Disorder Treatment. https://www.novonordisk.com/patient-information/norditropin (Accessed 22 June 2026).
[6] Abzena - AbP-800. https://www.abzena.com/biosimilars/abp-800/ (Accessed 22 June 2026).